Lexaria Bioscience Updates GLP-1-H24-4 Study Results

Lexaria Bioscience provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH study arms relative to the Rybelsus control study arm. At week 16, rough parity was reached between the DHT arms and the Rybelsus control as there were no statistically significant treatment differences observed in terms of the numerical least squares means changes from baseline in the secondary efficacy parameters of mean fasting glucose, cholesterol, and low density lipoprotein cholesterol specifically. While both DHT-semaglutide and Rybelsus reduced body weight during the Study, it was noteworthy that upon a separate body composition analysis performed in the Study using the dual-energy, X-ray absorptiometry / Bioelectrical Impedance Analysis methodology, at week 12, the DHT-semaglutide arm showed a modest numerical LSM reduction in fat mass of -1.08 kg and in total mass of -1.40 kg, accompanied by minimal reduction in lean mass of -0.41 kg. In contrast, the Rybelsus control arm achieved greater LSM reductions in fat mass of -3.55 kg and in total mass of -5.36 kg, but also had a notably higher reduction in lean mass of -1.72 kg. This finding is considered intriguing as it possibly points to proportionally lower lean mass to fat mass bodyweight reduction potential being achievable with DHT-semaglutide. While blood pressure analysis was not formally an efficacy endpoint of the Study, it was noteworthy that the DHT-cannabidiol arm achieved meaningful reductions in blood pressure. This is of special interest since the Study participants were not generally hypertensive. At week 4, a mean change of -4.6 mmHg in systolic blood pressure and -4.0 mmHg in diastolic blood pressure was evidenced in the DHT-CBD arm. Blood pressure reductions were also evident in this arm following completion of treatment at the week 16 follow up point with a mean change of -2.6 mmHg in systolic blood pressure and -3.0 mmHg in diastolic blood pressure reported.